BYL719 + Letrozole + Exemestane
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic or Locally-advanced Unresectable Breast Cancer
Conditions
Metastatic or Locally-advanced Unresectable Breast Cancer
Trial Timeline
May 1, 2013 → Feb 28, 2022
NCT ID
NCT01870505About BYL719 + Letrozole + Exemestane
BYL719 + Letrozole + Exemestane is a phase 1 stage product being developed by Novartis for Metastatic or Locally-advanced Unresectable Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01870505. Target conditions include Metastatic or Locally-advanced Unresectable Breast Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01870505 | Phase 1 | Completed |
Competing Products
20 competing products in Metastatic or Locally-advanced Unresectable Breast Cancer